Rna sequence-specific mediators of rna interference
CA 2404890 C · Owner: Tuschl, Thomas · Inventors: Zamore, Phillip D.; Bartel, David P.; Sharp, Phillip A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus , these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal which may be their specific , length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 2001 and granted November 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.